Stay updated with breaking news from Neogenomics inc. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
NeoGenomics (NASDAQ:NEO – Get Free Report) had its target price decreased by equities research analysts at Needham & Company LLC from $24.00 to $19.00 in a research note issued to investors on Tuesday, Benzinga reports. The brokerage presently has a “buy” rating on the medical research company’s stock. Needham & Company LLC’s price target indicates […] ....
NeoGenomics, Inc. (NASDAQ:NEO – Get Free Report) shares dropped 7.7% on Tuesday after Needham & Company LLC lowered their price target on the stock from $24.00 to $19.00. Needham & Company LLC currently has a buy rating on the stock. NeoGenomics traded as low as $13.70 and last traded at $14.05. Approximately 252,873 shares changed […] ....
NeoGenomics (NASDAQ:NEO – Get Free Report) updated its FY 2024 earnings guidance on Tuesday. The company provided EPS guidance of 0.000-0.040 for the period, compared to the consensus EPS estimate of -0.010. The company issued revenue guidance of $650.0 million-$660.0 million, compared to the consensus revenue estimate of $654.6 million. Analyst Upgrades and Downgrades NEO […] ....
NeoGenomics (NASDAQ:NEO – Get Free Report) issued an update on its FY 2024 earnings guidance on Tuesday morning. The company provided EPS guidance of 0.000-0.040 for the period, compared to the consensus EPS estimate of -0.010. The company issued revenue guidance of $650.0 million-$660.0 million, compared to the consensus revenue estimate of $654.6 million. Analyst […] ....